BBUSvsIBB
JPMorgan BetaBuilders U.S. Equity ETF against iShares Biotechnology ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BBUS | IBB | |
|---|---|---|
| Expense ratio | 0.020% | 0.45% |
| Assets | $9.4B | $10.9B |
| Net flow, 1 month | +$277M | +$272M |
| Net flow, 1 year | +$2.7B | +$1.8B |
| Return, YTD | +12.7% | +21.6% |
| Return, 1 year | +14.7% | +36.0% |
| Avg daily volume | 271K | 1.5M |
| Holdings | 575 | 221 |
| Listed | Mar 11, 2019 | Feb 5, 2001 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS